Rat Model News and Research

RSS

Athersys' MultiStem cell therapy provides multiple benefits in preclinical models of ischemic stroke

Medical researchers from The University of Texas Health Science Center at Houston (UTHealth) presented new research results at the American Heart Association International Stroke Conference that demonstrated how MultiStem-, a novel stem cell therapy being developed by Athersys, Inc. provided multiple benefits when administered in preclinical models of ischemic stroke.

11 Feb 2011

EHSI applauds promising new stem cell treatment for Parkinson's

Emerging Healthcare Solutions, Inc. applauded a new study today revealing a promising new stem cell treatment for Parkinson's.

10 Feb 2011

Research findings highlight potential for noninvasive MSC delivery to treat Parkinson disease

Successful intranasal delivery of stem cells to the brains of rats with Parkinson disease yielded significant improvement in motor function and reversed the dopamine deficiency characteristic of the disease.

9 Feb 2011

Stem cells delivered intranasally improve motor function in Parkinson's disease

Stem cells, delivered intranasally, were found to substantially improve motor function in Parkinson's disease in a study co-authored by William H. Frey II, Ph.D, Director of the Alzheimer's Research Center, part of HealthPartners Research Foundation. Frey collaborated with Lusine Danielyan, MD, of University Hospital of Tubingen in Germany.

4 Feb 2011

Blocking activation of delta-PKC enzyme could protect lungs from neutrophil-mediated damage

All of us may be able to breathe a little easier now that scientists from Pennsylvania have found a new therapeutic target for controlling dangerous inflammation in the lungs. A new research report in the January 2011 issue of the Journal of Leukocyte Biology (http://www.jleukbio.org) suggests that blocking the activation of an enzyme called delta-protein kinase C (delta-PKC) could protect the lungs from neutrophil-mediated damage, which can result in out of control inflammation.

5 Jan 2011

FDA clears ACT's IND to treat AMD using hESC derived RPE cells

Advanced Cell Technology, Inc., a leader in the field of regenerative medicine, announced today that the US Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application to treat Dry Age-Related Macular Degeneration (AMD) using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs).

3 Jan 2011

Fibrin microthreads support mesenchymal stem cell growth

A research team at Worcester Polytechnic Institute has demonstrated the feasibility of a novel technology that a surgeon could use to deliver stem cells to targeted areas of the body to repair diseased or damaged tissue, including cardiac muscle damaged by a heart attack. The technique involves bundling biopolymer microthreads into biological sutures and seeding the sutures with stem cells. The team has shown that the adult bone-marrow-derived stem cells will multiply while attached to the threads and retain their ability to differentiate and grow into other cell types.

10 Dec 2010

Neptune, Acasti completes preclinical program comparing CaPre with Lovaza

Neptune Technologies & Bioressources Inc. subsidiary, Acasti Pharma Inc., reports the completion of its preclinical program designed to compare the lipid management effects of Acasti's drug candidate CaPre versus prescription drug Lovaza.

25 Nov 2010

Sangamo presents Phase 2 clinical data in ALS at Society for Neuroscience Meeting

Sangamo BioSciences, Inc. announced today the presentation of Phase 2 clinical data from its ZFP Therapeutic program to develop SB-509, a zinc finger protein transcriptional activator (ZFP-TF) of the vascular endothelial growth factor (VEGF)-A gene as a treatment for ALS.

17 Nov 2010

Diabetic drug may retard growth of fluid-filled cysts in PKD: Research

Researchers report that a drug commonly used to treat diabetes may also retard the growth of fluid-filled cysts of the most common genetic disorder, polycystic kidney disease.

12 Nov 2010

Hygeia completes HYG-102 preclinical studies for vulvar and vaginal atrophy, and age-related skin fragility

Hygeia Therapeutics, Inc. announced today the successful completion of a series of preclinical studies for HYG-102, their lead product for the treatment of vulvar and vaginal atrophy (VVA) and age-related skin fragility. HYG-102 is the lead biodegradable estrogenic candidate in a portfolio of 23 similar compounds licensed from the laboratory of Dr. Richard Hochberg of Yale University.

11 Nov 2010

EVP-6124 receptor acts as co-agonist with ACh to enhance cognition

EnVivo Pharmaceuticals today announced it has discovered that EVP-6124, its alpha-7 nicotinic acetylcholine receptor agonist, possesses a novel mechanism not previously seen in the scientific community: it acts as a co-agonist with Acetylcholine (ACh) to enhance cognition.

9 Nov 2010

Roux-en-Y gastric bypass surgery effective for morbid obesity

Gastric bypass surgery decreases the preference for sweet-tasting substances in obese rats, a study finding that could help in developing safer treatments for the morbidly obese, according to Penn State College of Medicine researchers.

3 Nov 2010

Study explains statistical link between low aerobic exercise capacity and common diseases

Everybody knows that if you're physically fit, you're less likely to get a wide range of diseases. What most people don't know is that some people are "naturally" in better shape than others, and this variation in conditioning makes it difficult to test for disease risk and drug effectiveness in animal models.

2 Nov 2010

Plant-derived compound for treatment of nicotine addiction also effective against alcoholism

South Dakota State University researchers have demonstrated for the first time that a plant-derived compound used to treat nicotine addiction also has significant effects against alcohol addiction.

21 Oct 2010

Neupro improves quality of life in Parkinson's disease patients

People with Parkinson's disease who used once-daily Neupro® (rotigotine) in the RECOVER trial achieved improvements in quality of life, in addition to previously reported beneficial effects on motor and non-motor symptoms.

4 Oct 2010

Researchers develop microelectronic circuitry to guide axon growth in damaged brain

Researchers in the Midwest are developing microelectronic circuitry to guide the growth of axons in a brain damaged by an exploding bomb, car crash or stroke. The goal is to rewire the brain connectivity and bypass the region damaged by trauma, in order to restore normal behavior and movement.

28 Sep 2010

NIDA's Avant-Garde Awards support novel approaches for treating tobacco and cocaine addiction

A potential immunotherapy, a new gene therapy, an enzyme inhibitor, and a compound originally isolated from a Chinese herb are among the latest approaches scientists are proposing to treat addiction.

22 Sep 2010

Scientists to present preclinical pharmacology data on TRV120027 at Heart Failure Society of America Meeting

Trevena Inc., the leader in the discovery and development of G-protein coupled receptor biased ligands, today announced that its scientists are presenting two posters featuring compelling preclinical pharmacology data on TRV120027 at the 14th Annual Heart Failure Society of America Meeting being held September 12-15, 2010 in San Diego.

13 Sep 2010

Researchers demonstrate how insulin prepares cells for glucose uptake

Using high-resolution microscopy, researchers at the National Institutes of Health have shown how insulin prompts fat cells to take in glucose in a rat model. The findings were reported in the Sept. 8 issue of the journal Cell Metabolism.

9 Sep 2010